Literature DB >> 18652794

Medically serious adverse effects of newer antidepressants.

Rajnish Mago1, Rajeev Mahajan, Michael E Thase.   

Abstract

Although safer than tricyclic antidepressants and monoamine oxidase inhibitors, the newer antidepressants may be associated with certain medically serious adverse effects, of which cardiovascular adverse effects, seizures, abnormal bleeding, hyponatremia, and agranulocytosis are discussed in this review. Data regarding the incidence and risk factors are summarized, and strategies for reducing the risk of these adverse effects and managing them are suggested. Identification of risk factors, appropriate antidepressant choice, and, when possible, careful monitoring may substantially reduce the incidence of these adverse effects and the morbidity associated with them.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18652794     DOI: 10.1007/s11920-008-0041-2

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  73 in total

1.  Clinical pharmacology of mirtazapine: revisited.

Authors:  J Davis; R L Barkin
Journal:  Am Fam Physician       Date:  1999-09-15       Impact factor: 3.292

2.  Hyponatremia associated with bupropion, a case verified by rechallenge.

Authors:  Steven C Bagley; Deborah Yaeger
Journal:  J Clin Psychopharmacol       Date:  2005-02       Impact factor: 3.153

3.  Unusual & serious adverse effects of SSRIs: recognition & management.

Authors:  Robert H Howland
Journal:  J Psychosoc Nurs Ment Health Serv       Date:  2007-03       Impact factor: 1.098

4.  Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine.

Authors:  Michael E Thase; Pierre V Tran; Curtis Wiltse; Beth A Pangallo; Craig Mallinckrodt; Michael J Detke
Journal:  J Clin Psychopharmacol       Date:  2005-04       Impact factor: 3.153

5.  Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants.

Authors:  I M Whyte; A H Dawson; N A Buckley
Journal:  QJM       Date:  2003-05

6.  Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression.

Authors:  M S Thomé-Souza; E Kuczynski; K D Valente
Journal:  Epilepsy Behav       Date:  2007-02-15       Impact factor: 2.937

7.  The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate.

Authors:  Michael A Derby; Lu Zhang; Jill C Chappell; Celedon R Gonzales; J T Callaghan; Mark Leibowitz; Larry Ereshefsky; David Hoelscher; Philip T Leese; Malcolm I Mitchell
Journal:  J Cardiovasc Pharmacol       Date:  2007-06       Impact factor: 3.105

8.  Cardiovascular effects of bupropion in depressed patients with heart disease.

Authors:  S P Roose; G W Dalack; A H Glassman; S Woodring; B T Walsh; E G Giardina
Journal:  Am J Psychiatry       Date:  1991-04       Impact factor: 18.112

9.  Cardiogenic shock and status epilepticus after massive bupropion overdose.

Authors:  Florian Morazin; Agnès Lumbroso; Patrick Harry; Marcel Blaise; Alain Turcant; Philippe Montravers; Rémy Gauzit
Journal:  Clin Toxicol (Phila)       Date:  2007 Oct-Nov       Impact factor: 4.467

10.  Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine.

Authors:  J C Roos
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

View more
  8 in total

1.  A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients.

Authors:  Haeseong Park; Gwendolyn L Parker; Cecelia H Boardman; Monica M Morris; Thomas J Smith
Journal:  Support Care Cancer       Date:  2011-01-27       Impact factor: 3.603

2.  Antidepressants and the risk of abnormal bleeding during spinal surgery: a case–control study.

Authors:  Amirali Sayadipour; Rajnish Mago; Christopher K Kepler; R Bryan Chambliss; Kenneth M Certa; Alexander R Vaccaro; Todd J Albert; D Greg Anderson
Journal:  Eur Spine J       Date:  2012-10       Impact factor: 3.134

3.  Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes of surgery.

Authors:  Andrew D Auerbach; Eric Vittinghoff; Judith Maselli; Penelope S Pekow; John Q Young; Peter K Lindenauer
Journal:  JAMA Intern Med       Date:  2013-06-24       Impact factor: 21.873

Review 4.  A consensus statement for safety monitoring guidelines of treatments for major depressive disorder.

Authors:  Seetal Dodd; Gin S Malhi; John Tiller; Isaac Schweitzer; Ian Hickie; Jon Paul Khoo; Darryl L Bassett; Bill Lyndon; Philip B Mitchell; Gordon Parker; Paul B Fitzgerald; Marc Udina; Ajeet Singh; Steven Moylan; Francesco Giorlando; Carolyn Doughty; Christopher G Davey; Michael Theodoros; Michael Berk
Journal:  Aust N Z J Psychiatry       Date:  2011-09       Impact factor: 5.744

Review 5.  Clinical and biochemical manifestations of depression: relation to the neurobiology of stress.

Authors:  Phillip W Gold; Rodrigo Machado-Vieira; Maria G Pavlatou
Journal:  Neural Plast       Date:  2015-03-24       Impact factor: 3.599

6.  Clinical preference for factors in treatment of geriatric depression.

Authors:  Matthias W Riepe
Journal:  Neuropsychiatr Dis Treat       Date:  2014-12-22       Impact factor: 2.570

7.  Is depression the contraindication of anterior cervical decompression and fusion for cervical spondylosis?

Authors:  Xiaolu Chen; Xiao Li; Yu Gan; Ying Lu; Yu Tian; Yixiao Fu; Hanjie Yang; Ke Liu; Yinlian Pan; Xing Du
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-30       Impact factor: 6.055

8.  Effect of Chaihu-Shugan-San on the mRNA expression of the 5-HT1A receptor and cellular proliferation in the hippocampus of epileptic rats with depression.

Authors:  Ping Yang; Liang Li; Xue-Jun Liu; Xiong Cai; Mei-Zhen Sun; Jun-Feng He; Guang Zeng; Hui-Yong Huang
Journal:  Exp Ther Med       Date:  2015-11-13       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.